Vera Therapeutics, Inc. (VERA)
Vera Therapeutics, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Brisbane, CA, US. The stock last traded at $35.66, up 4.18% on the session, giving a market capitalisation of $2.56B. On trailing twelve-month figures it carries a trailing P/E of -6.09, a net margin of 0.0%. Its beta of 0.95 implies it has historically moved less than the broad market.
Vera Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of treatments for significant immunological disorders, primarily within the United States. Their leading therapeutic candidate is atacicept, a fusion protein that patients self-administer as a subcutaneous injection. This drug is currently undergoing Phase IIb clinical trials to treat immunoglobulin A nephropathy. The company is also advancing MAU868, a monoclonal antibody in Phase 2 clinical development, designed to combat BK viremia infections. Founded in 2016 and based in Brisbane, California, the organization operated as Trucode Gene Repair, Inc. until it rebranded to Vera Therapeutics, Inc. in April 2020.
Vera Therapeutics, Inc. is most often compared with the following Healthcare names: